UBS Cuts Price Target on Horizon Pharma (HZNP) After Meeting with Management
Tweet Send to a Friend
UBS maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $24.00 (from $39.00), after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
